SCHEMBL13837136

SCHEMBL13837136

O=C(O)C1CCCN1C(=O)Cc1c[nH]c2ccccc12

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C19 P33261 1/20 0.69
TACR1 P25103 1/20 0.56
TACR3 P29371 1/20 0.56
ALDH1A1 P00352 5/20 0.56
KMT2A Q03164 3/20 0.56
SMN1; SMN2 Q16637 3/20 0.56
MAPT P10636 2/20 0.56
MEN1 O00255 2/20 0.56
KDM4E B2RXH2 1/20 0.56
HPGD P15428 1/20 0.56
RAB9A P51151 1/20 0.53
MAPK1 P28482 2/20 0.52
L3MBTL1 Q9Y468 1/20 0.52
DNMT1 P26358 2/20 0.51
SIGMAR1 Q99720 1/20 0.51
DPP4 P27487 1/20 0.51
SLC6A2 P23975 1/20 0.50
FNTA P49354 1/20 0.50
FNTB P49356 1/20 0.50
AGTR2 P50052 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12480383 1.00 CYP2C19 (0.69) CYP2C19TACR1TACR3ALDH1A1KMT2A
SCHEMBL5742971 0.90 CYP2C19 (0.65) CYP2C19ALDH1A1KMT2ASMN1; SMN2MAPT
SCHEMBL5742979 0.90 CYP2C19 (0.65) CYP2C19ALDH1A1KMT2ASMN1; SMN2MAPT
SCHEMBL2473764 0.84 ALDH1A1 (0.52) CYP2C19ALDH1A1SMN1; SMN2UTS2R
SCHEMBL2473759 0.84 ALDH1A1 (0.52) CYP2C19ALDH1A1SMN1; SMN2UTS2R
SCHEMBL6039757 0.84 ALDH1A1 (0.52) CYP2C19ALDH1A1SMN1; SMN2UTS2R
SCHEMBL15245316 0.83 TACR1 (0.54) CYP2C19TACR1TACR3ALDH1A1KMT2A
SCHEMBL21641795 0.82 DPP4 (0.73) CYP2C19KMT2AMAPTMEN1KDM4E
SCHEMBL6438364 0.82 DPP4 (0.73) CYP2C19KMT2AMAPTMEN1KDM4E
SCHEMBL6438370 0.82 DPP4 (0.73) CYP2C19KMT2AMAPTMEN1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2661433-B1 INDOLE COMPOUNDS OR ANALOGUES THEREOF USEFUL FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) NOVARTIS AG (CH) 2017-08-16 EP disclosed
US-9085555-B2 Complement pathway modulators and uses thereof NOVARTIS AG (CH) 2015-07-21 US disclosed
US-20120295884-A1 Complement pathway modulators and uses thereof NOVARTIS AG (CH) 2012-11-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120295884-A1 Complement pathway modulators and uses thereof C5, C3AR1, C9 CYP2C19 188/4885TACR1 165/4885TACR3 656/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.